161 related articles for article (PubMed ID: 30367225)
1. [Predictive value of PD-L1 diagnostics].
Schildhaus HU
Pathologe; 2018 Nov; 39(6):498-519. PubMed ID: 30367225
[TBL] [Abstract][Full Text] [Related]
2. Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective.
Ionescu DN; Downes MR; Christofides A; Tsao MS
Curr Oncol; 2018 Jun; 25(3):e209-e216. PubMed ID: 29962847
[TBL] [Abstract][Full Text] [Related]
3. Deep Semi Supervised Generative Learning for Automated Tumor Proportion Scoring on NSCLC Tissue Needle Biopsies.
Kapil A; Meier A; Zuraw A; Steele KE; Rebelatto MC; Schmidt G; Brieu N
Sci Rep; 2018 Nov; 8(1):17343. PubMed ID: 30478349
[TBL] [Abstract][Full Text] [Related]
4. Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma.
Puladi B; Ooms M; Kintsler S; Houschyar KS; Steib F; Modabber A; Hölzle F; Knüchel-Clarke R; Braunschweig T
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503218
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate.
Witte HM; Gebauer N; Lappöhn D; Umathum VG; Riecke A; Arndt A; Steinestel K
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260165
[TBL] [Abstract][Full Text] [Related]
7. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
Chan TA; Yarchoan M; Jaffee E; Swanton C; Quezada SA; Stenzinger A; Peters S
Ann Oncol; 2019 Jan; 30(1):44-56. PubMed ID: 30395155
[TBL] [Abstract][Full Text] [Related]
8. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.
Stühler V; Maas JM; Bochem J; da Costa IA; Todenhöfer T; Stenzl A; Bedke J
World J Urol; 2019 Sep; 37(9):1773-1784. PubMed ID: 30374610
[TBL] [Abstract][Full Text] [Related]
9. Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma.
Zajac M; Boothman AM; Ben Y; Gupta A; Jin X; Mistry A; Sabalos C; Nielsen A; Manriquez G; Barker C; Antal J; Wang P; Patil P; Schechter N; Rebelatto MC; Walker J
Arch Pathol Lab Med; 2019 Jun; 143(6):722-731. PubMed ID: 30457897
[TBL] [Abstract][Full Text] [Related]
10. ASO Author Reflections: PD-1 Expression in Bacillus Calmette-Guérin-Relapsing Bladder Cancer.
Fukumoto K; Kikuchi E
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):982-983. PubMed ID: 30367304
[No Abstract] [Full Text] [Related]
11. PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory.
Vigliar E; Malapelle U; Iaccarino A; Acanfora G; Pisapia P; Clery E; De Luca C; Bellevicine C; Troncone G
J Clin Pathol; 2019 Jun; 72(6):412-417. PubMed ID: 30846480
[TBL] [Abstract][Full Text] [Related]
12. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC).
de Ruiter EJ; Mulder FJ; Koomen BM; Speel EJ; van den Hout MFCM; de Roest RH; Bloemena E; Devriese LA; Willems SM
Mod Pathol; 2021 Jun; 34(6):1125-1132. PubMed ID: 32759978
[TBL] [Abstract][Full Text] [Related]
13. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
Davis AA; Patel VG
J Immunother Cancer; 2019 Oct; 7(1):278. PubMed ID: 31655605
[TBL] [Abstract][Full Text] [Related]
14. [Erratum to: Predictive value of PD-L1 diagnostics].
Schildhaus HU
Pathologe; 2019 May; 40(3):275. PubMed ID: 31144079
[No Abstract] [Full Text] [Related]
15. PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs.
Park Y; Koh J; Na HY; Kwak Y; Lee KW; Ahn SH; Park DJ; Kim HH; Lee HS
Cancer Res Treat; 2020 Jul; 52(3):661-670. PubMed ID: 32019283
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
[TBL] [Abstract][Full Text] [Related]
17. "Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.
Torlakovic E; Lim HJ; Adam J; Barnes P; Bigras G; Chan AWH; Cheung CC; Chung JH; Couture C; Fiset PO; Fujimoto D; Han G; Hirsch FR; Ilie M; Ionescu D; Li C; Munari E; Okuda K; Ratcliffe MJ; Rimm DL; Ross C; Røge R; Scheel AH; Soo RA; Swanson PE; Tretiakova M; To KF; Vainer GW; Wang H; Xu Z; Zielinski D; Tsao MS
Mod Pathol; 2020 Jan; 33(1):4-17. PubMed ID: 31383961
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
[TBL] [Abstract][Full Text] [Related]
19. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Kojima T; Shah MA; Muro K; Francois E; Adenis A; Hsu CH; Doi T; Moriwaki T; Kim SB; Lee SH; Bennouna J; Kato K; Shen L; Enzinger P; Qin SK; Ferreira P; Chen J; Girotto G; de la Fouchardiere C; Senellart H; Al-Rajabi R; Lordick F; Wang R; Suryawanshi S; Bhagia P; Kang SP; Metges JP;
J Clin Oncol; 2020 Dec; 38(35):4138-4148. PubMed ID: 33026938
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK; Wu YL; Kudaba I; Kowalski DM; Cho BC; Turna HZ; Castro G; Srimuninnimit V; Laktionov KK; Bondarenko I; Kubota K; Lubiniecki GM; Zhang J; Kush D; Lopes G;
Lancet; 2019 May; 393(10183):1819-1830. PubMed ID: 30955977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
